These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33055192)

  • 1. Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes: A Systematic Review and Meta-Analysis.
    Chen Q; Wang Z; Zhou J; Chen Z; Li Y; Li S; Zhao H; Badve SV; Lv J
    Clin J Am Soc Nephrol; 2020 Nov; 15(11):1576-1586. PubMed ID: 33055192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.
    Kanji T; Gandhi M; Clase CM; Yang R
    BMC Nephrol; 2015 Apr; 16():58. PubMed ID: 25928556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.
    Sampson AL; Singer RF; Walters GD
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009460. PubMed ID: 29084343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease.
    Tiku A; Johnson DW; Badve SV
    Curr Opin Nephrol Hypertens; 2021 May; 30(3):346-352. PubMed ID: 33767063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
    Yu X; Gu M; Zhu Y; Zhang L; Kong W; Zou Y
    Clin Ther; 2022 May; 44(5):723-735.e6. PubMed ID: 35610080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
    Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
    BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis.
    Liu X; Zhai T; Ma R; Luo C; Wang H; Liu L
    Ren Fail; 2018 Nov; 40(1):289-297. PubMed ID: 29619870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.
    Bose B; Badve SV; Hiremath SS; Boudville N; Brown FG; Cass A; de Zoysa JR; Fassett RG; Faull R; Harris DC; Hawley CM; Kanellis J; Palmer SC; Perkovic V; Pascoe EM; Rangan GK; Walker RJ; Walters G; Johnson DW
    Nephrol Dial Transplant; 2014 Feb; 29(2):406-13. PubMed ID: 24042021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
    Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
    Zhang S; Xie Q; Xie S; Chen J; Deng Q; Zhong L; Guo J; Yu Y
    Pharmacotherapy; 2021 Sep; 41(9):781-791. PubMed ID: 34170566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis.
    Lin TC; Hung LY; Chen YC; Lo WC; Lin CH; Tam KW; Wu MY
    Medicine (Baltimore); 2019 Jul; 98(29):e16311. PubMed ID: 31335677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
    Jeon HJ; Oh J; Shin DH
    PLoS One; 2019; 14(6):e0218510. PubMed ID: 31206563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
    Lin YJ; Lin SY; Lin CH; Wang ST; Chang SS
    Clin Rheumatol; 2020 May; 39(5):1633-1648. PubMed ID: 31965378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
    Levy GD; Rashid N; Niu F; Cheetham TC
    J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies.
    Jeong HJ; Park WY; Kim SH; Dalbeth N; Son CN
    Semin Arthritis Rheum; 2022 Oct; 56():152073. PubMed ID: 35914389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.
    Li S; Yang H; Guo Y; Wei F; Yang X; Li D; Li M; Xu W; Li W; Sun L; Gao Y; Wang Y
    Sci Rep; 2016 Sep; 6():33082. PubMed ID: 27605442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum uric acid and the risk of cardiovascular and renal disease.
    Borghi C; Rosei EA; Bardin T; Dawson J; Dominiczak A; Kielstein JT; Manolis AJ; Perez-Ruiz F; Mancia G
    J Hypertens; 2015 Sep; 33(9):1729-41; discussion 1741. PubMed ID: 26136207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.